Market Outlook

By 2035, the U.S. Ambulatory Oncology Devices Market is projected to reach approximately USD 45.09 billion, expanding at a CAGR of 9.20% during the forecast period 2026–2035. The market is estimated at USD 18.70 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For the purpose of this report, the U.S. ambulatory oncology devices market includes medical devices, equipment, consumables, connected technologies, and procedure-support systems used predominantly for cancer diagnosis, treatment administration, minimally invasive intervention, monitoring, vascular access, and supportive care outside conventional inpatient hospitalization. The scope includes hospital outpatient oncology departments, community oncology practices, freestanding cancer and infusion centers, ambulatory surgery centers, physician offices, and selected home-based oncology pathways. Oncology pharmaceuticals, laboratory reagents, conventional pharmaceutical packaging, and devices designed almost exclusively for inpatient intensive-care use are excluded.

The market expanded from approximately USD 12.55 billion in 2021 to USD 16.80 billion in 2024, reflecting the normalization of oncology procedures after pandemic-related disruption, increasing outpatient chemotherapy volumes, expansion of community cancer networks, growing adoption of implanted ports and ambulatory infusion systems, and broader use of image-guided and minimally invasive cancer procedures. The market reached an estimated USD 18.70 billion in 2025 as provider organizations accelerated investments in infusion capacity, smart pumps, vascular access infrastructure, outpatient procedure rooms, remote symptom monitoring, and connected patient-management systems.

The demand foundation remains unusually strong. The United States was expected to record approximately 2.04 million new cancer diagnoses in 2025, equivalent to about 5,600 new cases per day, while more than 18.6 million people were living with a history of cancer. The U.S. cancer survivor population is expected to exceed 22 million by 2035. These trends are strategically important because ambulatory oncology device utilization is not determined only by initial cancer incidence. It is increasingly generated by repeated therapy cycles, long-duration survivorship, surveillance, maintenance therapy, venous-access management, outpatient procedures, toxicity monitoring, rehabilitation, and chronic cancer management.

The economic structure of U.S. cancer care is also supporting device investment. National cancer-related medical care expenditure has been projected to approach USD 246 billion by 2030. Payers and health systems therefore have strong incentives to move clinically appropriate treatment away from high-cost inpatient settings and toward hospital outpatient departments, community practices, specialized cancer centers, ambulatory facilities, and the home. Devices that enable safe decentralization of care, shorten infusion-chair occupancy, reduce emergency department utilization, simplify vascular access, automate dose delivery, improve patient surveillance, or increase procedure throughput are receiving greater strategic attention.

The market will nevertheless evolve unevenly. Conventional infusion systems will remain important, but subcutaneous formulations of major oncology therapies are changing administration economics. This shift can reduce the duration of certain intravenous infusions and therefore redistribute device spending toward injection support, smart monitoring, vascular access optimization, automated documentation, remote care, and higher-complexity ambulatory procedures. Manufacturers that understand this transition will be better positioned than suppliers relying only on historical chemotherapy-chair growth.

 

Introduction

According to the U.S. Ambulatory Oncology Devices Market Report, cancer care in the United States is undergoing a structural shift from hospital-centered episodic treatment toward distributed, longitudinal oncology management. A growing proportion of routine systemic therapy, supportive treatment, follow-up, diagnostic procedures, minor interventions, and symptom management can now be performed without inpatient admission.

Ambulatory oncology is therefore broader than chemotherapy infusion. The market includes smart infusion pumps, ambulatory infusion systems, elastomeric pumps, implanted ports, central venous access devices, PICCs, safety needles, closed administration accessories, biopsy and localization technologies, tumor ablation systems, image-guidance equipment, outpatient surgical devices, radiation-treatment infrastructure, physiologic monitoring, digital symptom tracking, and software layers that connect patients with oncology teams between visits.

The clinical model is supported by a large community cancer-care infrastructure. Thousands of U.S. oncologists practice in community settings, and hundreds of independent and multisite oncology organizations operate infusion clinics close to where patients live. In parallel, hospital systems are expanding satellite oncology centers and outpatient cancer campuses in suburban markets. Medicare payment policy also affects approximately 3,500 hospital outpatient facilities and more than 6,000 ambulatory surgical centers, creating a broad infrastructure capable of absorbing selected oncology procedures as reimbursement and clinical eligibility evolve.

The commercial opportunity is therefore driven by two simultaneous movements. First, more oncology activity is moving outside traditional inpatient settings. Second, cancer treatment itself is becoming more complex. Precision therapies, antibody-drug conjugates, immunotherapies, subcutaneous biologics, targeted therapies, interventional oncology, image-guided procedures, and longer survivorship require more sophisticated workflow coordination even when patients are treated on an ambulatory basis.

This creates a procurement environment in which device performance cannot be assessed only through acquisition price. Oncology administrators increasingly evaluate chair utilization, nursing workload, preparation time, alarm burden, medication-error risk, vascular-access complications, procedure duration, maintenance cost, cybersecurity, interoperability, consumable utilization, reimbursement capture, and patient experience.

The most strategically successful vendors will therefore sell workflow improvement rather than isolated equipment. Smart pumps must integrate with medication-management systems. Vascular-access products must reduce complications and simplify maintenance. Procedure devices must enable shorter recovery and same-day discharge. Monitoring technologies must identify deterioration before it becomes an emergency visit. Imaging and navigation systems must improve procedural confidence while fitting ambulatory room economics.

 

Key Market Drivers: What’s Fueling the U.S. Ambulatory Oncology Devices Market Boom?

The most fundamental growth driver is the scale of cancer incidence in the United States. More than two million Americans were expected to receive a new cancer diagnosis in 2025. Breast, prostate, lung, colorectal, hematologic, bladder, kidney, uterine, pancreatic, and other malignancies collectively generate millions of oncology consultations, infusion encounters, imaging procedures, biopsies, access-device placements, surveillance visits, and supportive-care episodes every year.

A second major driver is the expanding population living beyond an initial cancer diagnosis. Approximately 18.6 million cancer survivors were estimated in the United States in 2025, representing more than 5% of the national population. This population is expected to increase materially through 2035. Greater survivorship expands demand for long-term venous-access management, surveillance imaging, outpatient biopsies, chronic therapy administration, recurrence monitoring, rehabilitation, pain procedures, remote symptom management, and survivorship-focused diagnostics.

The third driver is migration from inpatient oncology to lower-cost outpatient care. Hospital systems and payers increasingly favor ambulatory treatment when patient acuity and therapy requirements allow it. Cancer patients who historically spent prolonged periods in hospitals can now receive many chemotherapy regimens, biologics, immunotherapies, transfusions, hydration, supportive medications, biopsies, catheter procedures, and selected image-guided interventions in outpatient facilities. This migration expands the installed base for compact pumps, procedural equipment, monitoring systems, vascular-access products, and digitally connected devices.

Community oncology is particularly important. Independent and multisite oncology practices can offer infusion, imaging, laboratory services, pharmacy services, clinical trials, navigation, and supportive care within a single ambulatory network. These practices frequently compete on accessibility, scheduling convenience, chair capacity, patient retention, and total episode economics. Equipment that improves throughput without requiring hospital-scale infrastructure is therefore commercially attractive.

A fourth driver is payer emphasis on total cost of oncology care. The CMS Enhancing Oncology Model reinforces accountability for quality and spending during systemic-therapy episodes. Participating oncology groups are expected to support navigation, 24-hour clinical access, evidence-based care, electronic patient-reported outcomes, and data-driven quality improvement. This model strengthens the business case for connected monitoring tools, symptom-management platforms, infusion documentation, automated patient engagement, and technologies capable of reducing unplanned utilization.

Initial CMS performance findings are strategically relevant: a large majority of evaluated participants generated savings relative to historical spending. The implication for device manufacturers is important. Technologies capable of demonstrating fewer complications, reduced emergency utilization, improved medication safety, lower nursing burden, or earlier intervention can increasingly be positioned as episode-economics tools rather than conventional capital purchases.

A fifth growth driver is continued innovation in systemic cancer therapy. New oncology drugs frequently require specialized administration, vascular access, observation, toxicity management, or combination-treatment workflows. Although pharmaceutical revenue itself is outside this market definition, each new regimen can alter device utilization. Some therapies increase infusion intensity, while others shorten administration time or migrate from IV to subcutaneous delivery. The device market therefore evolves with oncology pharmacology rather than independently from it.

A sixth driver is growth in minimally invasive oncology. Image-guided tumor biopsy, ablation, embolization, localization, venous-access placement, pain procedures, and selected cancer surgeries increasingly support same-day or short-stay pathways. Interventional radiology suites, outpatient hospitals, specialty centers, and ASCs are therefore becoming relevant purchasing environments for oncology-related needles, catheters, ablation platforms, navigation technologies, imaging systems, access products, and procedure-room equipment.

Finally, staffing economics are accelerating automation. Oncology nursing remains labor-intensive, particularly in infusion environments where clinicians manage multiple drugs, vascular-access devices, monitoring requirements, and adverse-event risks. Smart infusion systems, electronic documentation, barcode integration, standardized consumables, automated patient monitoring, and connected alarms can increase the number of patients supported per clinical team while reducing preventable workflow friction.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in ambulatory oncology is increasingly focused on reducing the amount of physical infrastructure and clinician time required for each treatment episode.

Smart infusion technology remains central. Modern infusion platforms are evolving from standalone pumps into medication-management systems connected with electronic health records, drug libraries, barcode workflows, alarm-management systems, and analytics platforms. In oncology, where drug regimens can have narrow dosing tolerances and high toxicity, interoperability and dose-error reduction are commercially significant differentiators.

Ambulatory pumps are also becoming strategically important for therapies that can be administered over extended periods outside the treatment center. Portable electronic pumps and elastomeric devices can allow selected patients to leave the infusion center while therapy continues, reducing chair occupancy and improving convenience. Growth in this category depends on reliable flow accuracy, user-friendly programming, disposable availability, patient education, remote support, and strong safety controls.

Vascular-access innovation is another major competitive area. Implanted ports, PICCs, central venous catheters, antimicrobial products, securement systems, ultrasound-guided access tools, safety needles, and maintenance accessories are essential to repeated oncology therapy. Manufacturers are increasingly competing on infection reduction, thrombosis risk, catheter durability, placement efficiency, visibility under imaging, and patient comfort.

The shift toward subcutaneous cancer therapy represents one of the most consequential workflow changes. FDA approvals of subcutaneous formulations of atezolizumab, nivolumab, pembrolizumab, amivantamab, and other biologic therapies demonstrate that some high-volume oncology treatments can move from prolonged IV administration toward shorter injections. This does not eliminate ambulatory device demand; it changes its composition. Infusion-chair time can fall while demand rises for rapid administration workflows, observation technology, connected documentation, injection support, patient monitoring, and higher-value treatment capacity.

Interventional oncology devices are also improving rapidly. Microwave ablation, radiofrequency ablation, cryoablation, embolization, biopsy navigation, localization systems, and advanced catheter technologies enable more cancer procedures to be performed percutaneously. These systems are increasingly evaluated through procedure time, imaging compatibility, anesthesia requirements, recovery duration, and ability to support same-day discharge.

Digitally connected oncology is emerging as the next major layer of differentiation. Electronic patient-reported outcomes, remote vital-sign monitoring, symptom tracking, temperature monitoring, wearable devices, and oncology-specific communication platforms can help clinical teams identify deterioration between treatment visits. The commercial value proposition becomes particularly strong when technology can prevent emergency department visits, identify febrile complications earlier, support dose management, or prioritize nursing outreach.

AI-enabled imaging and procedural planning are also expanding. AI applications can assist lesion identification, image segmentation, radiation planning, workflow prioritization, and procedural guidance. For ambulatory facilities with fewer subspecialists on-site than large academic hospitals, software that standardizes interpretation and reduces planning time may be especially valuable.

 

Segmentation Insights

The U.S. Ambulatory Oncology Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

Ambulatory Infusion and Drug-Delivery Systems

Ambulatory infusion and drug-delivery systems represent the largest product category in the market. The segment includes electronic infusion pumps, ambulatory pumps, volumetric pumps, syringe pumps, elastomeric devices, administration sets, oncology-compatible tubing, connectors, and related consumables. Oncology infusion centers require high device utilization because treatment regimens often involve repeated cycles and multiple supportive medications.

The category will remain a major revenue contributor, although growth will gradually move away from conventional pump replacement alone toward interoperability, smart drug libraries, remote monitoring, cybersecurity, and workflow analytics.

Vascular Access and Catheter Devices

Vascular-access products represent one of the most recurring and clinically essential segments. Implanted ports, PICCs, central venous catheters, port-access needles, securement products, flushing and locking accessories, ultrasound-guided placement devices, and closed connectors are widely used across chemotherapy and supportive therapy.

Growth is supported by rising treatment complexity and longer therapy duration. Providers increasingly value products that can reduce infections, thrombosis, repeated venipuncture, and treatment interruptions.

Interventional Oncology and Procedure Devices

This category includes biopsy devices, tumor-ablation systems, embolization products, drainage catheters, localization devices, access systems, surgical instruments, electrosurgical products, and selected minimally invasive oncology technologies.

The segment is gaining importance as image-guided intervention becomes an alternative or complement to open surgery in selected liver, lung, kidney, bone, and metastatic tumors. Ambulatory migration is particularly favorable for procedures associated with limited anesthesia requirements and rapid recovery.

Outpatient Imaging and Guidance Systems

Imaging and guidance devices include ultrasound, mobile C-arm systems, procedural imaging platforms, image-fusion solutions, radiation-planning equipment, navigation technologies, and compact diagnostic systems used in ambulatory oncology environments.

Capital intensity is higher than for consumables, but imaging represents a significant revenue pool because cancer centers increasingly seek integrated diagnostic, procedural, and treatment capabilities.

Monitoring and Supportive-Care Devices

This segment includes physiologic monitoring, remote patient-monitoring equipment, wearable devices, temperature monitoring, symptom-tracking technologies, treatment-chair monitoring, supportive respiratory technologies, and selected rehabilitation systems.

It is expected to be among the fastest-growing product categories because oncology management increasingly extends beyond the physical infusion center.

 

By Application

Breast Cancer

Breast cancer represents one of the largest ambulatory oncology applications because treatment frequently involves repeated systemic therapy, targeted biologics, surgery, radiation, imaging, vascular access, and long-term surveillance. The large U.S. patient base supports recurring demand across virtually every major ambulatory device category.

Increasing survivorship also extends the commercial opportunity beyond active treatment into follow-up imaging, lymphedema management, rehabilitation, and recurrent-disease monitoring.

Lung Cancer

Lung cancer remains one of the highest-acuity outpatient oncology applications. Immunotherapy, targeted treatment, biopsy, molecularly directed treatment pathways, image-guided intervention, radiation, and repeated imaging make the category device intensive.

Greater use of minimally invasive lung biopsy and ablation is expected to support procedure-device demand, while subcutaneous immunotherapy formulations could change future infusion-center workflow.

Hematologic Malignancies

Leukemia, lymphoma, and multiple myeloma require frequent systemic therapy, vascular access, infusion, transfusion support, monitoring, and longitudinal disease management. Multiple myeloma is particularly important because improving survival can create years of recurring outpatient treatment.

Hematologic oncology centers tend to require high infusion-chair utilization and sophisticated medication-management infrastructure, supporting premium smart-pump and monitoring adoption.

Colorectal and Gastrointestinal Cancers

Colorectal, pancreatic, gastric, hepatic, and other gastrointestinal malignancies generate substantial demand for prolonged systemic therapy, portable infusion, venous access, biopsy, interventional radiology, embolization, tumor ablation, drainage, and supportive care.

Portable ambulatory infusion systems are particularly relevant to certain multi-day chemotherapy protocols because patients can leave the treatment center while therapy continues.

Prostate and Other Genitourinary Cancers

Prostate, bladder, kidney, and related cancers create a diversified device opportunity across infusion, imaging, biopsy, minimally invasive surgery, ablation, catheterization, and surveillance.

Prostate cancer’s large survivor population gives the segment significant longitudinal value, while kidney tumors are increasingly relevant for image-guided biopsy and ablative intervention in selected patients.

 

By End User

Hospital Outpatient Departments

Hospital outpatient departments represent the largest end-user segment because they combine oncology specialists, pharmacy infrastructure, imaging, emergency backup, laboratory support, and access to advanced procedures.

Health systems increasingly operate multiple satellite oncology centers under a common purchasing platform. This creates opportunities for enterprise pump standardization, centralized drug libraries, common vascular-access contracts, and integrated remote-monitoring systems.

Community Oncology Practices

Community oncology practices are among the most strategically important end users because a substantial share of U.S. systemic cancer therapy is delivered close to patients’ homes.

These organizations prioritize patient throughput, infusion-chair utilization, reimbursement efficiency, predictable device maintenance, staff productivity, and purchasing flexibility. Vendors with scalable service models and strong consumable economics can gain significant share.

Freestanding Cancer and Infusion Centers

Freestanding centers focus heavily on outpatient treatment and therefore require high-reliability infusion, vascular-access, patient-monitoring, emergency-response, and medication-management infrastructure.

Their commercial model makes equipment utilization particularly important. Products that reduce chair time or enable more treatment appointments per day can generate measurable financial value.

Ambulatory Surgery Centers

ASCs represent a smaller but increasingly relevant oncology end-user category. Complex cancer surgery remains hospital-based, but selected breast procedures, biopsies, port placements, urologic oncology procedures, dermatologic oncology, gynecologic procedures, and other low-acuity interventions can occur in ambulatory facilities.

The segment favors compact devices, disposable procedure kits, rapid-turnover equipment, minimally invasive instruments, and technologies capable of supporting discharge within the same day.

Home-Based and Remote Oncology Care

Home oncology remains a developing segment but has high long-term potential. Selected portable infusions, toxicity surveillance, post-treatment monitoring, symptom tracking, and supportive therapies can increasingly be coordinated outside the clinic.

Growth will depend on patient selection, reimbursement, nursing availability, device usability, cybersecurity, emergency escalation protocols, and integration with oncology practice workflows.

 

By Technology Type

Smart Electronic Infusion Technology

Smart pumps with dose-error reduction, drug libraries, programmable safeguards, interoperability, and analytics represent the dominant advanced technology category.

Hospitals and large oncology networks increasingly prefer standardized platforms that reduce medication-management variation across multiple sites.

Portable and Disposable Delivery Technology

Portable electronic pumps and disposable elastomeric systems support extended therapy outside the clinic. Their value proposition is closely tied to patient mobility, chair-capacity optimization, simplicity, and reduced capital requirements.

The category is expected to remain important for regimens that require controlled administration over many hours or days.

Minimally Invasive Image-Guided Technology

Image-guided biopsy, ablation, embolization, navigation, localization, and catheter-based oncology devices represent one of the fastest-growing technological categories.

Expansion will be driven by procedure decentralization, same-day discharge, improved imaging precision, and demand for alternatives to conventional surgery in selected patients.

Connected Monitoring and Digital Oncology Devices

Remote monitoring systems, connected wearables, electronic symptom reporting, wireless physiologic monitoring, and cloud-based patient-management platforms are gaining strategic importance.

Their value will increasingly be measured by avoided acute-care utilization and improved patient prioritization rather than device sales alone.

AI-Assisted and Software-Enabled Systems

AI-assisted imaging, radiation planning, procedure guidance, infusion analytics, workflow optimization, and patient-risk stratification represent an emerging technology layer across ambulatory oncology.

Software revenue remains smaller than the installed hardware and consumables base, but software will increasingly influence vendor differentiation, switching costs, and enterprise procurement.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Ambulatory Oncology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance is shaped by cancer incidence, population aging, oncology-provider density, hospital consolidation, community-practice penetration, Medicare exposure, suburban population growth, academic cancer-center concentration, and the availability of outpatient procedural infrastructure.

The South is the largest regional market, representing an estimated USD 6.90 billion in 2025, while the West is projected to record the fastest CAGR through 2035. The Northeast maintains high per-patient technology intensity, while the Midwest provides a large, stable community oncology and regional health-system base.

South

The South accounted for approximately 36.9% of the U.S. market in 2025, with an estimated value of USD 6.90 billion. The region is projected to reach approximately USD 16.80 billion by 2035, representing a CAGR of roughly 9.31%.

The South benefits from a combination of population growth, large Medicare populations, substantial cancer burden, expanding suburban healthcare infrastructure, and strong penetration of community oncology.

Texas and Florida are the region’s two largest state opportunities. Texas was expected to record approximately 150,870 new cancer cases in 2025, making it one of the country’s largest absolute cancer markets. Houston, Dallas-Fort Worth, Austin, and San Antonio support extensive hospital systems, academic cancer programs, independent oncology organizations, infusion networks, and outpatient procedural facilities.

Texas is particularly attractive for device suppliers because ambulatory oncology demand is distributed across major metropolitan centers rather than concentrated in a single market. This favors enterprise contracts covering infusion equipment, vascular access, biopsy products, procedure devices, and remote-monitoring platforms across dozens of sites.

Florida was expected to record approximately 171,960 new cancer cases in 2025, second only to California in absolute volume. The state’s older demographic profile makes it particularly important for breast, prostate, lung, colorectal, hematologic, and multiple-primary cancer management.

Large retirement populations create high recurring demand for systemic treatment, vascular access, maintenance therapy, imaging, radiation, symptom monitoring, and survivorship services. Orlando, Tampa, Miami, Jacksonville, Fort Lauderdale, and other population centers support large oncology networks with substantial outpatient capacity.

North Carolina is another strategically important state, with approximately 71,320 projected new cases in 2025. The state combines strong population growth with major academic health systems and expanding community oncology infrastructure. Research Triangle institutions also influence early adoption of advanced cancer technologies.

Georgia, Virginia, Tennessee, Maryland, South Carolina, Alabama, Kentucky, Louisiana, Oklahoma, Arkansas, Mississippi, and West Virginia collectively provide a substantial secondary market. Georgia alone was expected to exceed 66,000 new cancer cases in 2025.

The commercial challenge across parts of the South is geographic access. Rural populations can be located far from comprehensive cancer centers. This increases the strategic relevance of satellite infusion clinics, portable therapy, tele-oncology integration, remote monitoring, and scalable devices that allow sophisticated oncology care to be delivered closer to the patient.

West

The West represented approximately USD 4.30 billion in 2025 and is expected to reach about USD 11.00 billion by 2035, corresponding to an estimated 9.85% CAGR, the fastest among the four U.S. regions.

California dominates the regional market. Approximately 199,980 new cancer cases were projected in California during 2025, the highest absolute number of any U.S. state.

California combines enormous patient volume with a high concentration of academic medical centers, integrated health systems, ambulatory surgical networks, cancer research institutions, biotechnology companies, and digital-health innovators. Los Angeles, San Diego, the San Francisco Bay Area, Sacramento, and Orange County support large and technologically advanced outpatient oncology ecosystems.

The state is particularly important for adoption of connected monitoring, AI-enabled imaging, radiation technology, interventional oncology, outpatient procedural systems, and digital patient-management platforms.

Arizona is a high-growth oncology device market due to population migration and a rapidly expanding older population. Approximately 42,560 new cancer cases were projected in 2025. Phoenix, Scottsdale, and Tucson are expanding specialty healthcare capacity, creating opportunities for infusion centers, ambulatory cancer facilities, and outpatient oncology procedures.

Washington generated approximately 46,500 projected new cancer cases in 2025 and has strong adoption of integrated care, digital health, precision medicine, and evidence-driven technology procurement. Seattle’s academic and biotechnology ecosystem also contributes to rapid evaluation of new oncology treatment workflows.

Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii provide smaller but meaningful opportunities. Colorado’s integrated delivery systems and population growth make Denver an increasingly important oncology market. Nevada benefits from rapid growth in Las Vegas and Reno, while Utah combines population growth with sophisticated regional referral care.

The West should gain incremental market share through 2035 because its provider organizations are relatively receptive to ambulatory care redesign, remote monitoring, AI, and digital integration.

Northeast

The Northeast represented an estimated USD 4.05 billion in 2025 and is projected to reach approximately USD 9.55 billion by 2035, reflecting an estimated 8.96% CAGR.

Although the region has slower population growth than the South and West, it has some of the highest oncology technology intensity in the country because of dense specialist networks, leading academic cancer centers, large hospital systems, clinical trial activity, and sophisticated payer markets.

New York is the dominant state. Approximately 123,430 new cancer cases were projected in 2025, creating one of the country’s largest oncology patient pools. New York City and surrounding metropolitan areas support high volumes of infusion, radiation, diagnostic imaging, biopsy, surgical oncology, and interventional treatment.

Pennsylvania represents another major market, with approximately 90,240 projected new cases in 2025. Philadelphia and Pittsburgh contain major academic and integrated healthcare systems, while substantial community oncology demand exists throughout the state.

New Jersey, Massachusetts, Connecticut, Maryland-adjacent markets, and the smaller New England states add further demand. New Jersey was expected to record nearly 60,000 new cases in 2025, while Massachusetts was expected to record approximately 44,000.

Massachusetts is disproportionately important relative to its population because of its academic medical centers, clinical research ecosystem, oncology biotechnology presence, and early evaluation of advanced therapies. Technologies validated in Boston cancer programs can influence adoption elsewhere in the U.S.

Procurement in the Northeast is typically evidence intensive. Vendors are frequently expected to provide clinical studies, cybersecurity documentation, health-economic justification, system integration, training capabilities, and measurable workflow benefits.

Midwest

The Midwest represented approximately USD 3.45 billion in 2025 and is expected to reach around USD 7.74 billion by 2035, corresponding to an estimated 8.42% CAGR.

Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota create a geographically broad market anchored by major metropolitan oncology hubs and regional referral networks.

Illinois was expected to record approximately 78,870 new cancer cases in 2025, with Chicago accounting for a substantial concentration of advanced oncology treatment. Large academic centers coexist with community practices and integrated health systems throughout the state.

Ohio was expected to record approximately 77,010 new cases, supporting strong outpatient oncology demand in Cleveland, Columbus, Cincinnati, and other metropolitan markets. The state has significant cancer-center infrastructure and a large population suitable for distributed ambulatory treatment.

Michigan, with approximately 66,040 projected new cases, also represents a major market. Detroit, Ann Arbor, Grand Rapids, and regional health systems generate meaningful demand for infusion, imaging, vascular access, radiation, and ambulatory procedure devices.

Minnesota is strategically significant because of its medical-device ecosystem and sophisticated health systems. Wisconsin, Indiana, Missouri, and Iowa provide stable community oncology demand and generally favor technologies with clear clinical benefit and predictable economics.

Rural portions of the Midwest remain underserved by advanced oncology infrastructure. As in rural Southern and Western markets, this creates potential for connected devices, portable therapy, tele-oncology-supported monitoring, and regional hub-and-spoke treatment models.

 

Key Market Players

The U.S. Ambulatory Oncology Devices Competitive Landscape is fragmented across infusion technology, vascular access, interventional oncology, imaging, radiation oncology, procedural devices, monitoring, and ambulatory infrastructure.

Competition is increasingly ecosystem based. Large manufacturers can combine capital equipment, consumables, connectivity, service contracts, and enterprise purchasing arrangements. Specialized companies compete through focused clinical differentiation, portable device design, image-guided intervention, vascular-access expertise, or lower-complexity ambulatory deployment.

Some of the key players operating across the U.S. ambulatory oncology device ecosystem include Becton, Dickinson and Company; Baxter International; B. Braun Medical; ICU Medical; Fresenius Kabi; Terumo Corporation; Moog Inc.; Eitan Medical; Avanos Medical; AngioDynamics; Teleflex; Merit Medical Systems; Cook Medical; Cardinal Health; Medline Industries; Nipro Corporation; Siemens Healthineers/Varian; GE HealthCare; Philips Healthcare; Elekta; Boston Scientific Corporation; Medtronic; Johnson & Johnson MedTech; Stryker; and Hologic.

BD, Baxter, B. Braun, ICU Medical, Fresenius Kabi, Moog, and Eitan Medical are especially relevant to infusion and ambulatory drug-delivery workflows. BD, Teleflex, AngioDynamics, Merit Medical, Cook Medical, and related suppliers compete across vascular access, biopsy, catheter, and minimally invasive procedure categories.

Siemens Healthineers/Varian and Elekta are highly relevant to radiation oncology infrastructure, while GE HealthCare, Philips, and Siemens Healthineers influence imaging and procedural guidance. Boston Scientific, Medtronic, Johnson & Johnson MedTech, AngioDynamics, and Merit Medical participate in interventional technologies relevant to image-guided cancer care.

Future competitive advantage will increasingly depend on interoperability, supply reliability, cybersecurity, consumable economics, clinical support, service responsiveness, enterprise contracting, reimbursement alignment, and measurable improvement in patient throughput.

 

Recent Developments

Recent developments demonstrate that U.S. ambulatory oncology is entering a period of significant workflow redesign.

In September 2024, the FDA approved the first subcutaneous formulation of atezolizumab for approved adult indications previously treated with intravenous atezolizumab. In December 2024, a subcutaneous nivolumab formulation was approved across multiple approved adult solid-tumor indications.

The trend accelerated during 2025. The FDA approved a subcutaneous formulation of pembrolizumab in September 2025 and a subcutaneous formulation of amivantamab in December 2025. These approvals are commercially important for ambulatory oncology because they can substantially reduce administration requirements for selected patients compared with conventional intravenous infusion.

For device manufacturers, the strategic implication is mixed. Certain pump and infusion-set utilization may decline for converted treatments, but oncology centers can use released chair capacity to treat more patients. At the same time, demand can shift toward injection workflows, patient monitoring, automated documentation, scheduling software, vascular-access optimization for combination therapy, and technologies supporting higher patient throughput.

CMS also expanded the Enhancing Oncology Model with a second participant cohort beginning July 1, 2025. The model places greater accountability on oncology practices for total episode cost, patient experience, care coordination, electronic patient-reported outcomes, and quality.

Early performance data subsequently indicated that approximately 79% of evaluated participants generated savings relative to historical spending. This creates an increasingly favorable environment for technologies that can demonstrate reductions in unplanned utilization, improve treatment adherence, facilitate proactive symptom management, or reduce clinical labor requirements.

The FDA’s broader oncology innovation pipeline is also increasing device complexity. During 2024 alone, the agency reported 17 novel oncology drug approvals alongside dozens of additional decisions expanding existing cancer therapies. Each new therapy can alter ambulatory administration patterns, patient monitoring requirements, observation time, and supportive-care workflows.

The competitive landscape is therefore moving toward integration. Manufacturers are developing device portfolios that connect infusion, access, procedural support, imaging, monitoring, software, and analytics. Oncology providers increasingly prefer technologies capable of functioning across multiple ambulatory sites rather than isolated devices requiring separate management systems.

 

Conclusion

The U.S. Ambulatory Oncology Devices Market Size & Share is positioned for significant expansion from approximately USD 18.70 billion in 2025 to USD 45.09 billion by 2035, representing a 9.20% CAGR during 2026–2035.

The market’s fundamental strength comes from the combination of more than two million annual cancer diagnoses, expanding survivorship, increasing treatment complexity, growth of community oncology, migration toward outpatient care, and pressure on providers to manage total episode costs.

The highest-value commercial opportunities will emerge around smart and connected infusion, vascular access, portable treatment delivery, minimally invasive oncology procedures, image-guided intervention, outpatient imaging, remote symptom monitoring, electronic patient-reported outcomes, and software that increases oncology workforce productivity.

Traditional infusion infrastructure will remain important, but manufacturers should not assume that future market growth will simply follow chemotherapy-chair volume. The emergence of subcutaneous biologics can materially shorten administration for selected treatments. This will favor providers and technologies capable of converting released clinical capacity into higher throughput and more efficient patient management.

Regional opportunity will remain led by the South because of population scale, aging demographics, and large cancer volumes, while the West is expected to record the fastest expansion due to population growth and accelerated adoption of digitally connected care. The Northeast will remain critical for premium technology adoption and clinical validation, while the Midwest will provide a durable community oncology and integrated health-system base.

At the state level, California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Michigan, New Jersey, Washington, Arizona, Massachusetts, Virginia, and Tennessee represent particularly important opportunities because they combine substantial cancer incidence with strong ambulatory oncology infrastructure.

For manufacturers, investors, providers, and market-entry teams evaluating this space, the central strategic question is not simply how many oncology devices will be purchased. The more important issue is which devices enable cancer treatment to migrate safely and economically into lower-acuity settings while improving provider productivity and patient experience.

The companies most likely to capture disproportionate growth through 2035 will be those that combine clinical performance with workflow economics. In the U.S. ambulatory oncology market, premium pricing will increasingly need to be justified through reduced chair time, fewer complications, better patient monitoring, easier deployment across multiple sites, lower nursing workload, and measurable impact on the total cost of cancer care.

 

TABLE OF CONTENT

1. U.S. Ambulatory Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Ambulatory Oncology Device Manufacturers
1.6.2. Component, Consumable and Contract Manufacturing Suppliers
1.6.3. Hospital Systems and Integrated Delivery Networks
1.6.4. Community Oncology Practices and Cancer Centers
1.6.5. Ambulatory Surgery Centers and Outpatient Procedure Facilities
1.6.6. Home Infusion and Remote Oncology Care Providers
1.6.7. Group Purchasing Organizations and Specialty Distributors
1.6.8. Payers, Regulators and Oncology Clinical Decision-Makers

What this section provides: This section defines the market boundary, study scope, methodology, assumptions, care-setting inclusion criteria, and stakeholder ecosystem so clients understand how the U.S. ambulatory oncology devices market is measured, segmented, and validated.

2. U.S. Ambulatory Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Ambulatory Oncology Site-of-Care Migration Snapshot
2.9. Key Technology and Procurement Priorities

What this section provides: This section gives decision-makers a concise view of market size, growth direction, outpatient oncology migration, major device demand pockets, competitive intensity, technology shifts, and priority commercial opportunities.

3. U.S. Ambulatory Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Survivorship Population
3.1.2. Shift from Inpatient to Outpatient and Community Oncology Care
3.1.3. Expansion of Ambulatory Infusion and Systemic Therapy Capacity
3.1.4. Growth in Minimally Invasive and Image-Guided Oncology Procedures
3.1.5. Increasing Adoption of Smart Infusion and Connected Drug-Delivery Systems
3.1.6. Expanding Vascular Access Requirements in Long-Duration Oncology Treatment
3.1.7. Growing Adoption of Remote Patient Monitoring and Electronic Symptom Tracking
3.1.8. Oncology Workforce Constraints and Need for Workflow Automation

3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Oncology Equipment
3.2.2. Reimbursement Pressure and Site-of-Care Payment Differentials
3.2.3. Product Safety, Infusion Error and Device Recall Risks
3.2.4. Cybersecurity and Interoperability Challenges
3.2.5. Oncology Nursing and Specialist Workforce Shortages
3.2.6. Changing Infusion Demand Due to Subcutaneous Oncology Therapies

3.3. Opportunities and Their Impact Analysis
3.3.1. Smart and Interoperable Oncology Infusion Platforms
3.3.2. Portable and Disposable Ambulatory Drug-Delivery Systems
3.3.3. Outpatient Interventional Oncology Expansion
3.3.4. Remote Toxicity Monitoring and Proactive Symptom Management
3.3.5. AI-Assisted Oncology Imaging and Procedure Guidance
3.3.6. Home-Based and Decentralized Oncology Care Models
3.3.7. Expansion of Community Oncology Networks
3.3.8. Value-Based Oncology Care and Episode-Economics Optimization

3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Ambulatory Oncology Clinical Workflow Economics Analysis
3.7. Infusion Chair Capacity and Patient Throughput Analysis
3.8. Hospital and Community Oncology Capital Procurement Behavior Analysis
3.9. Site-of-Care Migration Impact Analysis
3.10. Oncology Device Utilization and Replacement Cycle Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, workforce, technology, and operational forces shaping ambulatory oncology device demand and helps clients assess both market upside and execution risk.

4. U.S. Ambulatory Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Ambulatory Oncology
4.6. Application & Innovation Landscape
4.7. FDA Medical Device Regulatory Framework Analysis
4.8. CMS Reimbursement and Oncology Coverage Landscape
4.9. Hospital Outpatient and ASC Payment Environment
4.10. Value-Based Oncology Care and Enhancing Oncology Model Impact
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Cancer Initiatives and Public Health Programs
4.13. Impact of Escalating Geopolitical and Supply Chain Tensions
4.14. Oncology Value Analysis Committee Decision Framework
4.15. Cybersecurity and Interoperability Requirements
4.16. Device Purchasing Criteria Across Community Oncology Networks

What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, supply chains, connected-care adoption, value-based oncology, cybersecurity, and provider procurement dynamics.

5. U.S. Ambulatory Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Ambulatory Infusion and Drug-Delivery Systems
5.1.2.1. Smart Electronic Infusion Pumps
5.1.2.2. Ambulatory Infusion Pumps
5.1.2.3. Syringe Infusion Pumps
5.1.2.4. Volumetric Infusion Pumps
5.1.2.5. Elastomeric Infusion Pumps
5.1.2.6. Infusion Administration Sets and Accessories

5.1.3. Vascular Access and Catheter Devices
5.1.3.1. Implantable Ports
5.1.3.2. Peripherally Inserted Central Catheters
5.1.3.3. Central Venous Catheters
5.1.3.4. Port Access and Safety Needles
5.1.3.5. Securement and Stabilization Devices
5.1.3.6. Catheter Maintenance and Access Accessories

5.1.4. Interventional Oncology and Procedure Devices
5.1.4.1. Biopsy Devices
5.1.4.2. Tumor Ablation Systems
5.1.4.3. Embolization Devices
5.1.4.4. Drainage and Access Catheters
5.1.4.5. Tumor Localization Devices
5.1.4.6. Electrosurgical and Surgical Oncology Devices

5.1.5. Outpatient Imaging and Guidance Systems
5.1.5.1. Ultrasound Systems
5.1.5.2. Mobile C-Arm Systems
5.1.5.3. Image Fusion and Navigation Systems
5.1.5.4. Radiation Planning and Guidance Systems
5.1.5.5. Compact and Point-of-Care Imaging Systems

5.1.6. Monitoring and Supportive-Care Devices
5.1.6.1. Physiological Monitoring Devices
5.1.6.2. Remote Patient Monitoring Devices
5.1.6.3. Wearable Oncology Monitoring Devices
5.1.6.4. Temperature and Infection Monitoring Systems
5.1.6.5. Symptom and Treatment Response Monitoring Devices

What this section provides: This section identifies which ambulatory oncology device categories are expected to contribute the most revenue and which product classes offer the strongest growth opportunities through 2035.

6. U.S. Ambulatory Oncology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)

6.1.2. Breast Cancer
6.1.2.1. Systemic Therapy Administration
6.1.2.2. Image-Guided Biopsy and Localization
6.1.2.3. Ambulatory Surgical Procedures
6.1.2.4. Radiation Therapy Support
6.1.2.5. Survivorship and Remote Monitoring

6.1.3. Lung Cancer
6.1.3.1. Immunotherapy and Systemic Treatment
6.1.3.2. Image-Guided Biopsy
6.1.3.3. Tumor Ablation
6.1.3.4. Radiation Oncology
6.1.3.5. Remote Symptom and Respiratory Monitoring

6.1.4. Hematologic Malignancies
6.1.4.1. Leukemia
6.1.4.2. Lymphoma
6.1.4.3. Multiple Myeloma
6.1.4.4. Long-Duration Infusion and Vascular Access
6.1.4.5. Treatment Monitoring and Supportive Care

6.1.5. Colorectal and Gastrointestinal Cancers
6.1.5.1. Colorectal Cancer
6.1.5.2. Pancreatic Cancer
6.1.5.3. Gastric Cancer
6.1.5.4. Liver and Hepatobiliary Cancers
6.1.5.5. Portable Infusion and Interventional Oncology

6.1.6. Prostate and Other Genitourinary Cancers
6.1.6.1. Prostate Cancer
6.1.6.2. Bladder Cancer
6.1.6.3. Kidney Cancer
6.1.6.4. Ambulatory Biopsy and Procedure Support
6.1.6.5. Long-Term Surveillance and Monitoring

6.1.7. Other Cancers
6.1.7.1. Gynecologic Cancers
6.1.7.2. Head and Neck Cancers
6.1.7.3. Skin Cancer and Melanoma
6.1.7.4. Sarcoma and Other Solid Tumors

What this section provides: This section helps clients understand device demand by cancer type and identify clinical applications with strong ambulatory treatment volumes, procedure growth, recurring device utilization, and technology adoption potential.

7. U.S. Ambulatory Oncology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

7.1.2. Hospital Outpatient Departments
7.1.2.1. Academic Medical Center Oncology Departments
7.1.2.2. Integrated Health System Cancer Centers
7.1.2.3. Hospital-Owned Satellite Oncology Centers

7.1.3. Community Oncology Practices
7.1.3.1. Independent Oncology Practices
7.1.3.2. Multisite Community Oncology Networks
7.1.3.3. Physician-Owned Infusion Centers

7.1.4. Freestanding Cancer and Infusion Centers
7.1.4.1. Comprehensive Cancer Centers
7.1.4.2. Specialty Infusion Centers
7.1.4.3. Radiation and Multimodality Oncology Centers

7.1.5. Ambulatory Surgery Centers
7.1.5.1. Oncology-Focused ASCs
7.1.5.2. Multispecialty ASCs Performing Oncology Procedures
7.1.5.3. Office-Based Procedure Centers

7.1.6. Home-Based and Remote Oncology Care
7.1.6.1. Home Infusion Providers
7.1.6.2. Remote Patient Monitoring Providers
7.1.6.3. Hospital-at-Home and Decentralized Oncology Programs

What this section provides: This section explains which ambulatory care settings and customer groups are expected to drive device purchasing, recurring consumable use, procedure migration, capital investment, and connected oncology adoption.

8. U.S. Ambulatory Oncology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)

8.1.2. Smart Electronic Infusion Technology
8.1.2.1. Dose Error Reduction Systems
8.1.2.2. EHR-Integrated Infusion Systems
8.1.2.3. Automated Drug Libraries
8.1.2.4. Infusion Analytics Platforms

8.1.3. Portable and Disposable Delivery Technology
8.1.3.1. Portable Electronic Pumps
8.1.3.2. Elastomeric Delivery Systems
8.1.3.3. Disposable Infusion Technologies
8.1.3.4. Wearable Drug-Delivery Systems

8.1.4. Minimally Invasive Image-Guided Technology
8.1.4.1. Radiofrequency Ablation
8.1.4.2. Microwave Ablation
8.1.4.3. Cryoablation
8.1.4.4. Embolization Technologies
8.1.4.5. Image-Guided Biopsy and Localization

8.1.5. Connected Monitoring and Digital Oncology Devices
8.1.5.1. Remote Physiologic Monitoring
8.1.5.2. Connected Wearables
8.1.5.3. Electronic Symptom Monitoring
8.1.5.4. Wireless Patient Monitoring
8.1.5.5. Cloud-Based Oncology Device Platforms

8.1.6. AI-Assisted and Software-Enabled Systems
8.1.6.1. AI-Assisted Oncology Imaging
8.1.6.2. AI-Enabled Procedure Planning
8.1.6.3. Infusion Workflow Optimization Software
8.1.6.4. Patient Risk Stratification Platforms
8.1.6.5. Radiation Planning and Decision-Support Software

What this section provides: This section evaluates technology platforms reshaping ambulatory oncology care, including smart infusion, portable delivery, minimally invasive intervention, connected monitoring, AI, and software-enabled workflows.

9. U.S. Ambulatory Oncology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)

9.1.2. Direct Hospital and Health System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Community Oncology Network Procurement
9.1.6. Distributor and Specialty Supplier Sales
9.1.7. Ambulatory Surgery Center Procurement
9.1.8. Home Infusion and Remote Care Procurement
9.1.9. Equipment Leasing and Managed-Service Agreements

What this section provides: This section helps clients understand how ambulatory oncology devices are purchased in the U.S., including enterprise standardization, GPO influence, community oncology purchasing, distributor channels, capital leasing, and outpatient procurement behavior.

10. U.S. Ambulatory Oncology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cancer Incidence and Treatment Volume Analysis
10.1.4. Regional Outpatient Oncology Infrastructure Analysis
10.1.5. Regional Infusion Capacity and Community Oncology Network Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics
10.1.7. Regional Site-of-Care Migration Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Ambulatory Oncology Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Ambulatory Oncology Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Ambulatory Oncology Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Ambulatory Oncology Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis of ambulatory oncology device demand, helping clients identify priority U.S. geographies, cancer-treatment hubs, community oncology clusters, outpatient procedure opportunities, technology-adoption hotspots, and state-level commercial opportunities.

11. U.S. Ambulatory Oncology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Company Profiles

11.3.1. Becton, Dickinson and Company
11.3.2. Baxter International Inc.
11.3.3. B. Braun Medical Inc.
11.3.4. ICU Medical, Inc.
11.3.5. Fresenius Kabi
11.3.6. Terumo Corporation
11.3.7. Moog Inc.
11.3.8. Eitan Medical
11.3.9. Avanos Medical, Inc.
11.3.10. AngioDynamics, Inc.
11.3.11. Teleflex Incorporated
11.3.12. Merit Medical Systems, Inc.
11.3.13. Cook Medical
11.3.14. Cardinal Health, Inc.
11.3.15. Medline Industries, LP
11.3.16. Nipro Corporation
11.3.17. Siemens Healthineers / Varian
11.3.18. GE HealthCare
11.3.19. Philips Healthcare
11.3.20. Elekta AB
11.3.21. Boston Scientific Corporation
11.3.22. Medtronic plc
11.3.23. Johnson & Johnson MedTech
11.3.24. Stryker Corporation
11.3.25. Hologic, Inc.

11.4. Competitive Benchmarking by Product Portfolio
11.5. Competitive Benchmarking by Ambulatory Care Setting
11.6. Smart Infusion and Drug-Delivery Competitive Landscape
11.7. Vascular Access Competitive Landscape
11.8. Interventional Oncology Competitive Landscape
11.9. Imaging and Radiation Oncology Competitive Landscape
11.10. Remote Monitoring and Connected Oncology Competitive Landscape
11.11. Mergers, Acquisitions and Strategic Partnerships
11.12. U.S. Product Launch and FDA Approval Analysis
11.13. Enterprise Contracting and GPO Positioning

Note: Each company profile will include company overview, ambulatory oncology device portfolio, U.S. market strategy, financial positioning, technology pipeline, regulatory updates, partnerships, acquisitions, major customer segments, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, product-portfolio positioning, ambulatory oncology exposure, innovation direction, contracting strategy, and strategic intelligence on major device companies.

12. U.S. Ambulatory Oncology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. Smart and Interoperable Infusion Systems
12.2.2. Subcutaneous Oncology Drug-Delivery Transition
12.2.3. Portable and Wearable Infusion Platforms
12.2.4. AI-Assisted Oncology Imaging
12.2.5. Image-Guided Tumor Ablation and Interventional Oncology
12.2.6. Remote Patient Monitoring and Electronic Patient-Reported Outcomes
12.2.7. Home-Based Oncology Treatment Technologies
12.2.8. Automated Oncology Workflow and Decision-Support Systems

12.3. Emerging Business Trends
12.3.1. Migration from Hospital to Community Oncology
12.3.2. Growth of Oncology Supergroups and Multisite Networks
12.3.3. Expansion of Same-Day Cancer Procedures
12.3.4. Value-Based Oncology Purchasing
12.3.5. Vendor Consolidation and Platform-Based Procurement

12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Adoption Roadmap, 2026–2035
12.7. Future Infusion Chair Utilization and Capacity Outlook
12.8. Site-of-Care Shift Forecast
12.9. Long-Term Oncology Device Replacement Cycle Outlook

What this section provides: This section prepares clients for future technology shifts, site-of-care migration, market structure changes, investment opportunities, device utilization patterns, and potential adoption scenarios through 2035.

13. U.S. Ambulatory Oncology Devices Market: Strategic Recommendations

13.1. Recommendations for Device Manufacturers
13.2. Recommendations for Hospital and Health System Oncology Programs
13.3. Recommendations for Community Oncology Networks
13.4. Recommendations for Ambulatory Surgery Centers
13.5. Recommendations for Home Infusion and Remote Oncology Providers
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Startups
13.9. Go-to-Market Strategy Considerations
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. U.S. State-Level Market Entry Prioritization
13.12. GPO and IDN Contracting Strategy
13.13. Clinical Evidence and Health-Economic Strategy
13.14. Reimbursement and Market Access Strategy
13.15. Digital Integration and Cybersecurity Strategy

What this section provides: This section converts market intelligence into actionable strategies for market entry, product positioning, portfolio development, contracting, geographic expansion, capital allocation, reimbursement planning, and competitive differentiation.

14. U.S. Ambulatory Oncology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Market Modeling Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Regulatory and Reimbursement Information Disclaimer

What this section provides: This section clarifies the report’s scope limitations, forecasting assumptions, market-modeling boundaries, legal conditions, third-party data usage, and regulatory and reimbursement information limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Ambulatory Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Ambulatory Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Ambulatory Oncology Devices Market: Key Assumptions
TABLE 5: U.S. Ambulatory Oncology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Ambulatory Oncology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Ambulatory Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Ambulatory Oncology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Ambulatory Oncology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Ambulatory Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Ambulatory Oncology Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Ambulatory Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Ambulatory Oncology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Ambulatory Oncology Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Ambulatory Oncology Devices Market: Site-of-Care Migration and Technology Procurement Snapshot
TABLE 16: U.S. Ambulatory Oncology Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. Ambulatory Oncology Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. Ambulatory Oncology Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. Ambulatory Oncology Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. Ambulatory Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. Ambulatory Oncology Devices Market: Ambulatory Oncology Clinical Workflow Economics Matrix
TABLE 22: U.S. Ambulatory Oncology Devices Market: Infusion Chair Capacity and Patient Throughput Analysis
TABLE 23: U.S. Ambulatory Oncology Devices Market: Hospital and Community Oncology Capital Procurement Behavior Matrix
TABLE 24: U.S. Ambulatory Oncology Devices Market: Site-of-Care Migration Impact Analysis
TABLE 25: U.S. Ambulatory Oncology Devices Market: Device Utilization and Replacement Cycle Analysis
TABLE 26: U.S. Ambulatory Oncology Devices Market: PESTEL Analysis
TABLE 27: U.S. Ambulatory Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 28: U.S. Ambulatory Oncology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. Ambulatory Oncology Devices Market: Value Chain Analysis
TABLE 30: U.S. Ambulatory Oncology Devices Market: Supply Chain Analysis
TABLE 31: U.S. Ambulatory Oncology Devices Market: Digitalization and Connected Ambulatory Oncology Impact
TABLE 32: U.S. Ambulatory Oncology Devices Market: Application & Innovation Landscape
TABLE 33: U.S. Ambulatory Oncology Devices Market: FDA Medical Device Regulatory Framework Analysis
TABLE 34: U.S. Ambulatory Oncology Devices Market: CMS Reimbursement and Oncology Coverage Landscape
TABLE 35: U.S. Ambulatory Oncology Devices Market: Hospital Outpatient and ASC Payment Environment
TABLE 36: U.S. Ambulatory Oncology Devices Market: Value-Based Oncology Care and Enhancing Oncology Model Impact
TABLE 37: U.S. Ambulatory Oncology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 38: U.S. Ambulatory Oncology Devices Market: Government Cancer Initiatives and Public Health Programs
TABLE 39: U.S. Ambulatory Oncology Devices Market: Impact of Escalating Geopolitical and Supply Chain Tensions
TABLE 40: U.S. Ambulatory Oncology Devices Market: Oncology Value Analysis Committee Decision Framework
TABLE 41: U.S. Ambulatory Oncology Devices Market: Cybersecurity and Interoperability Requirements
TABLE 42: U.S. Ambulatory Oncology Devices Market: Community Oncology Device Purchasing Criteria
TABLE 43: U.S. Ambulatory Oncology Devices Market: Product Category Snapshot, 2025
TABLE 44: Segment Dashboard; Definition and Scope, by Product Category
TABLE 45: U.S. Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 46: U.S. Ambulatory Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 47: U.S. Ambulatory Oncology Devices Market: Ambulatory Infusion and Drug-Delivery Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Ambulatory Oncology Devices Market: Vascular Access and Catheter Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Ambulatory Oncology Devices Market: Interventional Oncology and Procedure Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Ambulatory Oncology Devices Market: Outpatient Imaging and Guidance Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Ambulatory Oncology Devices Market: Monitoring and Supportive-Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Ambulatory Oncology Devices Market: Application Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by Application
TABLE 54: U.S. Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 55: U.S. Ambulatory Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 56: U.S. Ambulatory Oncology Devices Market: Breast Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Ambulatory Oncology Devices Market: Lung Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Ambulatory Oncology Devices Market: Hematologic Malignancies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Ambulatory Oncology Devices Market: Colorectal and Gastrointestinal Cancers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Ambulatory Oncology Devices Market: Prostate and Other Genitourinary Cancers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Ambulatory Oncology Devices Market: Other Cancers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Ambulatory Oncology Devices Market: End User Snapshot, 2025
TABLE 63: Segment Dashboard; Definition and Scope, by End User
TABLE 64: U.S. Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 65: U.S. Ambulatory Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 66: U.S. Ambulatory Oncology Devices Market: Hospital Outpatient Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Ambulatory Oncology Devices Market: Community Oncology Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Ambulatory Oncology Devices Market: Freestanding Cancer and Infusion Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Ambulatory Oncology Devices Market: Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Ambulatory Oncology Devices Market: Home-Based and Remote Oncology Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Ambulatory Oncology Devices Market: Technology Type Snapshot, 2025
TABLE 72: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 73: U.S. Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 74: U.S. Ambulatory Oncology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 75: U.S. Ambulatory Oncology Devices Market: Smart Electronic Infusion Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Ambulatory Oncology Devices Market: Portable and Disposable Delivery Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Ambulatory Oncology Devices Market: Minimally Invasive Image-Guided Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Ambulatory Oncology Devices Market: Connected Monitoring and Digital Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Ambulatory Oncology Devices Market: AI-Assisted and Software-Enabled Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Ambulatory Oncology Devices Market: Procurement Channel Snapshot, 2025
TABLE 81: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 82: U.S. Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 83: U.S. Ambulatory Oncology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 84: U.S. Ambulatory Oncology Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Ambulatory Oncology Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Ambulatory Oncology Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. Ambulatory Oncology Devices Market: Community Oncology Network Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. Ambulatory Oncology Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: U.S. Ambulatory Oncology Devices Market: Ambulatory Surgery Center Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: U.S. Ambulatory Oncology Devices Market: Home Infusion and Remote Care Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: U.S. Ambulatory Oncology Devices Market: Equipment Leasing and Managed-Service Agreements Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: U.S. Ambulatory Oncology Devices Market: Regional Snapshot, 2025
TABLE 93: Segment Dashboard; Definition and Scope, by Region
TABLE 94: U.S. Ambulatory Oncology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 95: U.S. Ambulatory Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 96: U.S. Ambulatory Oncology Devices Market: Regional Cancer Incidence and Treatment Volume Analysis
TABLE 97: U.S. Ambulatory Oncology Devices Market: Regional Outpatient Oncology Infrastructure and Site-of-Care Migration Analysis
TABLE 98: West Region U.S. Ambulatory Oncology Devices Market: Regional Overview and Trends
TABLE 99: West Region U.S. Ambulatory Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 100: West Region U.S. Ambulatory Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 101: West Region U.S. Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 102: West Region U.S. Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 106: California Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 107: California Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 108: California Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 109: California Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 110: California Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 111: Washington Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 112: Washington Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 113: Washington Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 114: Washington Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 115: Washington Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 116: Arizona Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 117: Arizona Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 118: Arizona Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 119: Arizona Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 120: Arizona Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 121: Colorado Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 122: Colorado Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 123: Colorado Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 124: Colorado Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 125: Colorado Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 126: Oregon Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 127: Oregon Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 128: Oregon Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 129: Oregon Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 130: Oregon Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 131: Utah Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 132: Utah Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 133: Utah Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: Utah Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 135: Utah Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 136: Nevada Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 137: Nevada Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 138: Nevada Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 139: Nevada Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 140: Nevada Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 141: New Mexico Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 142: New Mexico Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 143: New Mexico Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 144: New Mexico Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 145: New Mexico Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 146: Idaho Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 147: Idaho Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 148: Idaho Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 149: Idaho Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 150: Idaho Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 151: Montana Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 152: Montana Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 153: Montana Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 154: Montana Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 155: Montana Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 156: Wyoming Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 157: Wyoming Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 158: Wyoming Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 159: Wyoming Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 160: Wyoming Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 161: Alaska Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 162: Alaska Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 163: Alaska Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 164: Alaska Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 165: Alaska Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 166: Hawaii Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 167: Hawaii Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 168: Hawaii Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 169: Hawaii Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 170: Hawaii Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 171: Northeast Region U.S. Ambulatory Oncology Devices Market: Regional Overview and Trends
TABLE 172: Northeast Region U.S. Ambulatory Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 173: Northeast Region U.S. Ambulatory Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 174: Northeast Region U.S. Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 175: Northeast Region U.S. Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 176: Northeast Region U.S. Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 177: Northeast Region U.S. Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 178: Northeast Region U.S. Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 179: New York Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 180: New York Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 181: New York Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 182: New York Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 183: New York Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 184: Massachusetts Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 185: Massachusetts Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 186: Massachusetts Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 187: Massachusetts Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 188: Massachusetts Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 189: New Jersey Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 190: New Jersey Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 191: New Jersey Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 192: New Jersey Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 193: New Jersey Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 194: Pennsylvania Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 195: Pennsylvania Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 196: Pennsylvania Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 197: Pennsylvania Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 198: Pennsylvania Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 199: Connecticut Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 200: Connecticut Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 201: Connecticut Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 202: Connecticut Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 203: Connecticut Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 204: Maine Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 205: Maine Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 206: Maine Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 207: Maine Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 208: Maine Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 209: Vermont Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 210: Vermont Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 211: Vermont Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 212: Vermont Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 213: Vermont Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 214: New Hampshire Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 215: New Hampshire Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 216: New Hampshire Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 217: New Hampshire Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 218: New Hampshire Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 219: Rhode Island Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 220: Rhode Island Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 221: Rhode Island Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 222: Rhode Island Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 223: Rhode Island Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 224: Delaware Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 225: Delaware Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 226: Delaware Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 227: Delaware Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 228: Delaware Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 229: South Region U.S. Ambulatory Oncology Devices Market: Regional Overview and Trends
TABLE 230: South Region U.S. Ambulatory Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 231: South Region U.S. Ambulatory Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 232: South Region U.S. Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 233: South Region U.S. Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 234: South Region U.S. Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 235: South Region U.S. Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 236: South Region U.S. Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 237: Texas Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 238: Texas Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 239: Texas Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 240: Texas Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 241: Texas Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 242: Florida Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 243: Florida Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 244: Florida Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 245: Florida Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 246: Florida Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 247: Georgia Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 248: Georgia Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 249: Georgia Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 250: Georgia Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 251: Georgia Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 252: North Carolina Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 253: North Carolina Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 254: North Carolina Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 255: North Carolina Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 256: North Carolina Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 257: Tennessee Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 258: Tennessee Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 259: Tennessee Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 260: Tennessee Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 261: Tennessee Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 262: South Carolina Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 263: South Carolina Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 264: South Carolina Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 265: South Carolina Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 266: South Carolina Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 267: Alabama Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 268: Alabama Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 269: Alabama Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 270: Alabama Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 271: Alabama Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 272: Mississippi Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 273: Mississippi Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 274: Mississippi Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 275: Mississippi Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 276: Mississippi Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 277: Louisiana Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 278: Louisiana Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 279: Louisiana Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 280: Louisiana Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 281: Louisiana Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 282: Arkansas Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 283: Arkansas Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 284: Arkansas Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 285: Arkansas Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 286: Arkansas Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 287: Kentucky Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 288: Kentucky Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 289: Kentucky Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 290: Kentucky Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 291: Kentucky Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 292: Oklahoma Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 293: Oklahoma Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 294: Oklahoma Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 295: Oklahoma Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 296: Oklahoma Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 297: Virginia Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 298: Virginia Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 299: Virginia Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 300: Virginia Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 301: Virginia Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 302: Maryland Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 303: Maryland Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 304: Maryland Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 305: Maryland Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 306: Maryland Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 307: West Virginia Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 308: West Virginia Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 309: West Virginia Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 310: West Virginia Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 311: West Virginia Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 312: Midwest Region U.S. Ambulatory Oncology Devices Market: Regional Overview and Trends
TABLE 313: Midwest Region U.S. Ambulatory Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 314: Midwest Region U.S. Ambulatory Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 315: Midwest Region U.S. Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 316: Midwest Region U.S. Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 317: Midwest Region U.S. Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 318: Midwest Region U.S. Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 319: Midwest Region U.S. Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 320: Illinois Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 321: Illinois Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 322: Illinois Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 323: Illinois Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 324: Illinois Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 325: Ohio Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 326: Ohio Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 327: Ohio Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 328: Ohio Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 329: Ohio Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 330: Michigan Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 331: Michigan Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 332: Michigan Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 333: Michigan Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 334: Michigan Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 335: Minnesota Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 336: Minnesota Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 337: Minnesota Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 338: Minnesota Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 339: Minnesota Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 340: Indiana Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 341: Indiana Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 342: Indiana Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 343: Indiana Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 344: Indiana Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 345: Wisconsin Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 346: Wisconsin Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 347: Wisconsin Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 348: Wisconsin Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 349: Wisconsin Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 350: Missouri Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 351: Missouri Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 352: Missouri Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 353: Missouri Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 354: Missouri Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 355: Iowa Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 356: Iowa Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 357: Iowa Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 358: Iowa Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 359: Iowa Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 360: Kansas Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 361: Kansas Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 362: Kansas Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 363: Kansas Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 364: Kansas Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 365: Nebraska Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 366: Nebraska Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 367: Nebraska Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 368: Nebraska Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 369: Nebraska Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 370: North Dakota Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 371: North Dakota Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 372: North Dakota Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 373: North Dakota Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 374: North Dakota Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 375: South Dakota Ambulatory Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 376: South Dakota Ambulatory Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 377: South Dakota Ambulatory Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 378: South Dakota Ambulatory Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 379: South Dakota Ambulatory Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 380: U.S. Ambulatory Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 381: U.S. Ambulatory Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 382: U.S. Ambulatory Oncology Devices Market: Company Positioning Matrix
TABLE 383: U.S. Ambulatory Oncology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 384: U.S. Ambulatory Oncology Devices Market: Competitive Benchmarking by Ambulatory Care Setting
TABLE 385: U.S. Ambulatory Oncology Devices Market: Smart Infusion and Drug-Delivery Competitive Landscape
TABLE 386: U.S. Ambulatory Oncology Devices Market: Vascular Access Competitive Landscape
TABLE 387: U.S. Ambulatory Oncology Devices Market: Interventional Oncology Competitive Landscape
TABLE 388: U.S. Ambulatory Oncology Devices Market: Imaging and Radiation Oncology Competitive Landscape
TABLE 389: U.S. Ambulatory Oncology Devices Market: Remote Monitoring and Connected Oncology Competitive Landscape
TABLE 390: U.S. Ambulatory Oncology Devices Market: Mergers, Acquisitions and Strategic Partnerships
TABLE 391: U.S. Ambulatory Oncology Devices Market: U.S. Product Launch and FDA Approval Analysis
TABLE 392: U.S. Ambulatory Oncology Devices Market: Enterprise Contracting and GPO Positioning
TABLE 393: Becton, Dickinson and Company: Company Profile
TABLE 394: Baxter International Inc.: Company Profile
TABLE 395: B. Braun Medical Inc.: Company Profile
TABLE 396: ICU Medical, Inc.: Company Profile
TABLE 397: Fresenius Kabi: Company Profile
TABLE 398: Terumo Corporation: Company Profile
TABLE 399: Moog Inc.: Company Profile
TABLE 400: Eitan Medical: Company Profile
TABLE 401: Avanos Medical, Inc.: Company Profile
TABLE 402: AngioDynamics, Inc.: Company Profile
TABLE 403: Teleflex Incorporated: Company Profile
TABLE 404: Merit Medical Systems, Inc.: Company Profile
TABLE 405: Cook Medical: Company Profile
TABLE 406: Cardinal Health, Inc.: Company Profile
TABLE 407: Medline Industries, LP: Company Profile
TABLE 408: Nipro Corporation: Company Profile
TABLE 409: Siemens Healthineers / Varian: Company Profile
TABLE 410: GE HealthCare: Company Profile
TABLE 411: Philips Healthcare: Company Profile
TABLE 412: Elekta AB: Company Profile
TABLE 413: Boston Scientific Corporation: Company Profile
TABLE 414: Medtronic plc: Company Profile
TABLE 415: Johnson & Johnson MedTech: Company Profile
TABLE 416: Stryker Corporation: Company Profile
TABLE 417: Hologic, Inc.: Company Profile
TABLE 418: U.S. Ambulatory Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 419: U.S. Ambulatory Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 420: U.S. Ambulatory Oncology Devices Market: Emerging Business Trends
TABLE 421: U.S. Ambulatory Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 422: U.S. Ambulatory Oncology Devices Market: Investment Prioritization Matrix
TABLE 423: U.S. Ambulatory Oncology Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 424: U.S. Ambulatory Oncology Devices Market: Future Infusion Chair Utilization and Capacity Outlook
TABLE 425: U.S. Ambulatory Oncology Devices Market: Site-of-Care Shift Forecast, 2026–2035
TABLE 426: U.S. Ambulatory Oncology Devices Market: Long-Term Device Replacement Cycle Outlook
TABLE 427: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 428: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Hospital and Health System Oncology Programs
TABLE 429: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Community Oncology Networks
TABLE 430: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Ambulatory Surgery Centers
TABLE 431: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Home Infusion and Remote Oncology Providers
TABLE 432: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 433: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 434: U.S. Ambulatory Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 435: U.S. Ambulatory Oncology Devices Market: Go-to-Market Strategy Considerations
TABLE 436: U.S. Ambulatory Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 437: U.S. Ambulatory Oncology Devices Market: U.S. State-Level Market Entry Prioritization
TABLE 438: U.S. Ambulatory Oncology Devices Market: GPO and IDN Contracting Strategy
TABLE 439: U.S. Ambulatory Oncology Devices Market: Clinical Evidence and Health-Economic Strategy
TABLE 440: U.S. Ambulatory Oncology Devices Market: Reimbursement and Market Access Strategy
TABLE 441: U.S. Ambulatory Oncology Devices Market: Digital Integration and Cybersecurity Strategy
TABLE 442: U.S. Ambulatory Oncology Devices Market: Scope Limitation
TABLE 443: U.S. Ambulatory Oncology Devices Market: Data Use Limitation
TABLE 444: U.S. Ambulatory Oncology Devices Market: Forecasting Limitation
TABLE 445: U.S. Ambulatory Oncology Devices Market: Market Modeling Limitation
TABLE 446: U.S. Ambulatory Oncology Devices Market: Legal Disclaimer
TABLE 447: U.S. Ambulatory Oncology Devices Market: Third-Party Data Disclaimer
TABLE 448: U.S. Ambulatory Oncology Devices Market: Regulatory and Reimbursement Information Disclaimer

List of Figures

FIGURE 1: U.S. Ambulatory Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Value Chain Analysis
FIGURE 5: Supply Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Ambulatory Oncology Clinical Workflow Economics Framework
FIGURE 12: Infusion Chair Capacity and Patient Throughput Framework
FIGURE 13: Ambulatory Oncology Capital Procurement Decision Framework
FIGURE 14: U.S. Ambulatory Oncology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. Ambulatory Oncology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 17: U.S. Ambulatory Oncology Site-of-Care Migration Framework
FIGURE 18: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Ambulatory Infusion and Drug-Delivery Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Vascular Access and Catheter Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Interventional Oncology and Procedure Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Outpatient Imaging and Guidance Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Monitoring and Supportive-Care Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Breast Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Lung Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Hematologic Malignancies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Colorectal and Gastrointestinal Cancers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Prostate and Other Genitourinary Cancers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Other Cancers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 34: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Hospital Outpatient Departments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Community Oncology Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Freestanding Cancer and Infusion Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Ambulatory Surgery Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Home-Based and Remote Oncology Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 41: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Smart Electronic Infusion Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Portable and Disposable Delivery Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Minimally Invasive Image-Guided Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Connected Monitoring and Digital Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: AI-Assisted and Software-Enabled Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 48: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Community Oncology Network Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Ambulatory Surgery Center Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Home Infusion and Remote Care Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Equipment Leasing and Managed-Service Agreements Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 58: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: West Region U.S. Ambulatory Oncology Devices Market Share and Leading Players, 2025
FIGURE 60: West Region Market Share Analysis by State, 2025
FIGURE 61: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: California Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Washington Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Arizona Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Colorado Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Oregon Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Utah Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Nevada Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New Mexico Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Idaho Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Montana Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Wyoming Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Alaska Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Hawaii Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Northeast Region U.S. Ambulatory Oncology Devices Market Share and Leading Players, 2025
FIGURE 76: Northeast Region Market Share Analysis by State, 2025
FIGURE 77: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New York Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Massachusetts Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Jersey Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Pennsylvania Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Connecticut Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Maine Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Vermont Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: New Hampshire Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Rhode Island Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Delaware Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: South Region U.S. Ambulatory Oncology Devices Market Share and Leading Players, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Texas Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Florida Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Georgia Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: North Carolina Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Tennessee Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: South Carolina Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Alabama Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Mississippi Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Louisiana Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Arkansas Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Kentucky Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Oklahoma Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Virginia Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Maryland Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: West Virginia Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Midwest Region U.S. Ambulatory Oncology Devices Market Share and Leading Players, 2025
FIGURE 107: Midwest Region Market Share Analysis by State, 2025
FIGURE 108: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Illinois Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Ohio Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Michigan Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Minnesota Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Indiana Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Wisconsin Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Missouri Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Iowa Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Kansas Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Nebraska Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: North Dakota Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: South Dakota Ambulatory Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 122: Company Positioning Matrix
FIGURE 123: Key Player Product Portfolio Benchmarking
FIGURE 124: Competitive Benchmarking by Ambulatory Oncology Care Setting
FIGURE 125: Smart Infusion and Drug-Delivery Competitive Landscape
FIGURE 126: Vascular Access Competitive Landscape
FIGURE 127: Interventional Oncology Competitive Landscape
FIGURE 128: Imaging and Radiation Oncology Competitive Landscape
FIGURE 129: Remote Monitoring and Connected Oncology Competitive Landscape
FIGURE 130: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 131: U.S. Product Launch and FDA Approval Landscape
FIGURE 132: Enterprise Contracting and GPO Positioning Framework
FIGURE 133: Ambulatory Oncology Device Innovation Roadmap
FIGURE 134: Smart and Interoperable Infusion Technology Adoption Roadmap
FIGURE 135: Portable and Wearable Drug-Delivery Technology Roadmap
FIGURE 136: Interventional Oncology Technology Opportunity Map
FIGURE 137: Remote Patient Monitoring and Electronic Symptom Tracking Growth Roadmap
FIGURE 138: Ambulatory Oncology Site-of-Care Migration Roadmap
FIGURE 139: Future Market Scenario Analysis, 2026–2035
FIGURE 140: Disruptive Technologies Impact Matrix
FIGURE 141: Emerging Business Trends Matrix
FIGURE 142: Investment Prioritization Matrix
FIGURE 143: Technology Adoption Roadmap, 2026–2035
FIGURE 144: Future Infusion Chair Utilization and Capacity Outlook
FIGURE 145: Strategic Growth Roadmap for U.S. Ambulatory Oncology Device Companies
FIGURE 146: Go-to-Market Strategy Framework
FIGURE 147: Product Positioning and Portfolio Expansion Framework
FIGURE 148: U.S. State-Level Market Entry Prioritization Map
FIGURE 149: Reimbursement and Market Access Strategy Framework
FIGURE 150: Digital Integration and Cybersecurity Strategy Framework
FIGURE 151: Report Scope and Disclaimer Framework